T M Allen

Summary

Affiliation: University of Alberta
Country: Canada

Publications

  1. ncbi request reprint Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers
    Janny X Zhang
    Department of Pharmacology, University of Alberta, Edmonton, AB, Canada T6G 2H7
    Pharmacol Res 49:185-98. 2004
  2. ncbi request reprint Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes
    Puja Sapra
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
    Clin Cancer Res 10:2530-7. 2004
  3. ncbi request reprint Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer
    Gregory J R Charrois
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    Biochim Biophys Acta 1663:167-77. 2004
  4. ncbi request reprint Ligand-targeted therapeutics in anticancer therapy
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    Nat Rev Cancer 2:750-63. 2002
  5. ncbi request reprint Use of the post-insertion method for the formation of ligand-coupled liposomes
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    Cell Mol Biol Lett 7:217-9. 2002
  6. ncbi request reprint Drug delivery systems: entering the mainstream
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton T6G 2H7, Canada
    Science 303:1818-22. 2004
  7. ncbi request reprint Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Alberta, Edmonton, Canada
    Clin Cancer Res 11:3567-73. 2005
  8. ncbi request reprint Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton, AB, Canada
    Anticancer Agents Med Chem 6:513-23. 2006
  9. ncbi request reprint Liposomal drug formulations. Rationale for development and what we can expect for the future
    T M Allen
    Department of Pharmacology, University of Alberta, Edmonton, Canada
    Drugs 56:747-56. 1998
  10. ncbi request reprint Adventures in targeting
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada
    J Liposome Res 12:5-12. 2002

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers
    Janny X Zhang
    Department of Pharmacology, University of Alberta, Edmonton, AB, Canada T6G 2H7
    Pharmacol Res 49:185-98. 2004
    ..The presence of either cleavable or non-cleavable mPEG-lipids at concentrations of 5 mol% or higher in the DOPE/CHEMS liposomes inhibited the release of doxorubicin from these liposomes in response to acid pH...
  2. ncbi request reprint Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes
    Puja Sapra
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
    Clin Cancer Res 10:2530-7. 2004
    ..We also examine the effect of targeting immunoliposomes with antibody combinations in an attempt to increase the total number of binding sites (apparent antigen density) at the target cell surface...
  3. ncbi request reprint Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer
    Gregory J R Charrois
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    Biochim Biophys Acta 1663:167-77. 2004
    ..The liposomes with the slowest rate of drug leakage had the best therapeutic activity of the formulations tested...
  4. ncbi request reprint Ligand-targeted therapeutics in anticancer therapy
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    Nat Rev Cancer 2:750-63. 2002
    ..This increases the exposure of the malignant cells, and reduces the exposure of normal cells, to the ligand-targeted therapeutics...
  5. ncbi request reprint Use of the post-insertion method for the formation of ligand-coupled liposomes
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    Cell Mol Biol Lett 7:217-9. 2002
  6. ncbi request reprint Drug delivery systems: entering the mainstream
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton T6G 2H7, Canada
    Science 303:1818-22. 2004
    ..Furthermore, there is considerable interest in exploiting the advantages of DDS for in vivo delivery of new drugs derived from proteomics or genomics research and for their use in ligand-targeted therapeutics...
  7. ncbi request reprint Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Alberta, Edmonton, Canada
    Clin Cancer Res 11:3567-73. 2005
    ..The toxicities could be reduced and even overcome by targeting with anti-CD19 antibodies. For these formulations, therapeutic effects were intermediate between those found for liposomes with the fastest and slowest drug release rates...
  8. ncbi request reprint Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton, AB, Canada
    Anticancer Agents Med Chem 6:513-23. 2006
    ..This review will focus on how alteration of these properties can impact the therapeutic efficacy and side effect profiles of DDS...
  9. ncbi request reprint Liposomal drug formulations. Rationale for development and what we can expect for the future
    T M Allen
    Department of Pharmacology, University of Alberta, Edmonton, Canada
    Drugs 56:747-56. 1998
    ..An understanding of how liposome association can alter drug properties can lead to their rational development in the treatment of many diseases...
  10. ncbi request reprint Adventures in targeting
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada
    J Liposome Res 12:5-12. 2002
    ..These results should aid in the rational design of applications for immunoliposomal drugs in the future...
  11. ncbi request reprint A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer
    J N Moreira
    Department of Pharmacology, University of Alberta, Edmonton, Canada
    Biochim Biophys Acta 1514:303-17. 2001
    ..e., anticancer drugs, genes or antisense oligonucleotides, into target cells has the potential to improve therapy of SCLC...
  12. ncbi request reprint Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer
    E H Moase
    Department of Pharmacology, University of Alberta, Edmonton, Canada
    Biochim Biophys Acta 1510:43-55. 2001
    ....
  13. ncbi request reprint In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach
    D L Iden
    Department of Pharmacology, University of Alberta, Edmonton, AB, Canada T6G 2H7
    Biochim Biophys Acta 1513:207-16. 2001
    ..Overall, the results demonstrate that the post-insertion technique is a simple, flexible and effective means for preparing targeted liposomal drugs for clinical applications...
  14. ncbi request reprint Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells
    T Ishida
    Department of Pharmacology, University of Alberta, Edmonton, Canada
    Biochim Biophys Acta 1515:144-58. 2001
    ..These results suggest that targeted pH-sensitive formulations of drugs may be able to increase the therapeutic efficacy of entrapped drugs...
  15. ncbi request reprint Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments
    Puja Sapra
    Department of Pharmacology, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
    Clin Cancer Res 10:1100-11. 2004
    ....
  16. doi request reprint Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer
    Kimberley M Laginha
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
    J Drug Target 16:605-10. 2008
    ..Breast cancer tumors contained the highest total levels of DXR and the highest levels of bioavailable DXR when anti-HER2/neu-targeted liposomes were used, and the targeted liposomes also resulted in the greatest level of tumor control...
  17. ncbi request reprint Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs
    Puja Sapra
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7 Canada
    Cancer Res 62:7190-4. 2002
    ..The therapeutic advantage of targeting internalizing versus noninternalizing epitopes has been directly demonstrated...
  18. ncbi request reprint Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv
    Wilson W K Cheng
    Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
    J Control Release 126:50-8. 2008
    ..SIL-DXR targeted via HD37 Fab', which had the longest circulation half-life, appeared to be slightly more effective in prolonging survival times than SIL-DXR targeted via either HD37-CCH or HD37 mAb...
  19. ncbi request reprint Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells
    W W K Cheng
    Dept of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada T6G 2H7
    Biochim Biophys Acta 1768:21-9. 2007
    ..Our results suggest that anti-CD19 scFv constructs should be explored further for their potential in treating B-lymphoid leukemias and lymphomas...
  20. ncbi request reprint Targeting Stealth liposomes in a murine model of human small cell lung cancer
    J N Moreira
    Department of Pharmacology, University of Alberta, Edmonton, Canada
    Biochim Biophys Acta 1515:167-76. 2001
    ..Stealth liposomes containing DXR have potential as a therapy against human SCLC tumors...
  21. ncbi request reprint Targeted delivery of antisense oligonucleotides in cancer
    F Pastorino
    Department of Pharmacology 9-31 MSB, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
    J Control Release 74:69-75. 2001
    ..The formulations have long-circulation times in vivo, and evaluation for in vivo antitumor activity is currently underway...
  22. ncbi request reprint Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors
    Kimberley M Laginha
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
    Clin Cancer Res 11:6944-9. 2005
    ..We have developed a method for measuring levels of bioavailable (released) doxorubicin in vivo in tumors that will allow therapeutic activity to be correlated with bioavailable drug levels...
  23. ncbi request reprint Use of the post-insertion method for the formation of ligand-coupled liposomes
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    Cell Mol Biol Lett 7:889-94. 2002
    ..This allows the ligand-targeted therapeutics to be tailored to the needs of individual patients...
  24. ncbi request reprint Ligand-targeted liposomal anticancer drugs
    P Sapra
    Department of Pharmacology, University of Alberta, Edmonton AB, Canada, T6G 2H7
    Prog Lipid Res 42:439-62. 2003
    ..The time is rapidly approaching where we will see translation of anticancer drugs entrapped in LTLs to the clinic...
  25. ncbi request reprint Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity
    Gregory J R Charrois
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
    J Pharmacol Exp Ther 306:1058-67. 2003
    ....
  26. ncbi request reprint Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives
    Janny X Zhang
    Department of Pharmacology, 9 70 Medical Sciences Bldg, University of Alberta, Edmonton, Alta, Canada T6G 2H7
    J Control Release 86:323-38. 2003
    ..PEG-containing micellar formulations may be a promising delivery system for benzoporphyrin monoesters for clinical applications...
  27. ncbi request reprint Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity
    Gregory J R Charrois
    Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
    Biochim Biophys Acta 1609:102-8. 2003
    ..All formulations delayed tumor growth, with liposomes of 100 or 157 nm being equally efficacious and superior to liposomes of 255 nm...
  28. ncbi request reprint Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity
    João N Moreira
    Department of Pharmacology, University of Alberta, Edmonton, Canada
    Pharm Res 19:265-9. 2002
    ..Antagonist G-targeted liposomes (PLG) were prepared and loaded with doxorubicin and their cellular association and cytotoxicity were evaluated using the human small cell lung cancer H69 cell line...
  29. ncbi request reprint Dual role of melanins and melanin precursors as photoprotective and phototoxic agents: inhibition of ultraviolet radiation-induced lipid peroxidation
    S Schmitz
    Department of Physiology, University of Alberta, Edmonton, Canada
    Photochem Photobiol 61:650-5. 1995
    ..These results suggest that melanin precursors may have an important role in the protection of skin against the harmful effects of UVR including photocarcinogenesis...
  30. ncbi request reprint Comparative evaluation of two purification methods of anti-CD19-c-myc-His6-Cys scFv
    Dipankar Das
    Department of Pharmacology, University of Alberta, Edmonton, AB, Canada T6G 2H7
    Protein Expr Purif 39:199-208. 2005
    ....
  31. ncbi request reprint Advantages of liposomal delivery systems for anthracyclines
    Theresa M Allen
    Department of Pharmacology, University of Alberta School of Medicine, Edmonton, Alberta, Canada
    Semin Oncol 31:5-15. 2004
    ..It has circulation times between those of PLD and NPLD. This article reviews the advantages of liposomal delivery systems in general and the divergent approaches that have been taken in developing these agents...
  32. ncbi request reprint Distribution of photosensitizers in bladder cancer spheroids: implications for intravesical instillation of photosensitizers for photodynamic therapy of bladder cancer
    Zhengwen Xiao
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    J Pharm Pharm Sci 8:536-43. 2005
    ..Uniform intratumor distribution of sufficient photosensitizer is one of the important aspects of photodynamic therapy for solid tumors...
  33. ncbi request reprint The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis
    Zhaoyu Li
    Department of Biochemistry and Canadian Institutes of Health Research Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, Alberta T6G 2S2 Canada
    Cell Metab 3:321-31. 2006
    ..The results have clinical implications as patients with nonalcoholic steatohepatitis have a decreased ratio of PC to PE compared to control livers...
  34. ncbi request reprint Ligand-targeted liposomes for cancer treatment
    Puja Sapra
    Immunomedics, Inc, Morris Plains, NJ 07940, USA
    Curr Drug Deliv 2:369-81. 2005
    ..Ligand-targeted liposomes have shown considerable promise in preclinical xenograft models and are poised for clinical development...
  35. ncbi request reprint Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice
    Fabio Pastorino
    Differentiation Therapy Unit, Laboratory of Oncology, G Gaslini Children s Hospital, Genoa, Italy 16148
    Cancer Res 63:86-92. 2003
    ..In conclusion, Fab'-SIL[DXR] formulations led to the total inhibition of metastatic growth of human NB in a nude mouse metastatic model. This formulation should receive clinical evaluation as adjuvant therapy of NB...
  36. ncbi request reprint Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy
    Fabio Pastorino
    Laboratory of Oncology, G Gaslini Children s Hospital, Genoa, Italy
    Cancer Res 66:10073-82. 2006
    ..Long-term survivors were obtained only in animals treated with the combined tumor- and vascular-targeted formulations, confirming the pivotal role of combination therapies in treating aggressive metastatic neuroblastoma...
  37. ncbi request reprint Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison
    Gerben A Koning
    Department of Cell Biology, Section Liposome Research, Groningen University Institute for Drug Exploration, Faculty of Medical Sciences, University of Groningen, A Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Pharm Res 20:1249-57. 2003
    ..Evaluate the effectiveness of distal-end coupling of a tumor-specific antibody to liposomal polyethylene glycol (PEG) chains to improve target binding and reduce interference by macrophage uptake...
  38. ncbi request reprint In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma
    Lizzia Raffaghello
    Laboratory of Oncology, G Gaslini Children s Hospital, Genoa, Italy
    Int J Cancer 104:559-67. 2003
    ..0001). Anti-GD2 liposomal HPR should receive clinical evaluation as adjuvant therapy of neuroblastoma...
  39. ncbi request reprint Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system
    Sajid Hussain
    Department of Biochemistry, University of Zurich, Zurich, Switzerland
    Mol Cancer Ther 6:3019-27. 2007
    ..Our data show the promise of EpCAM-directed nanovesicular drug delivery for targeted therapy of solid tumors...
  40. ncbi request reprint Transendothelial movement of liposomes in vitro mediated by cancer cells, neutrophils or histamine
    Felicia Antohe
    Institute of Cellular Biology and Pathology N Simionescu, Bucharest, Romania
    J Liposome Res 14:1-25. 2004
    ..These results have important implications for the therapeutic use of liposome in the treatment of cancer or other inflammatory processes...
  41. ncbi request reprint Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma
    Chiara Brignole
    Differentiation Therapy Unit, Laboratory of Oncology, G Gaslini Children s Hospital, Largo G Gaslini 5, Genoa 16148, Italy
    Cancer Lett 197:199-204. 2003
    ..0001). Fab'-SIL[DXR] prevented the establishment and the metastatic growth of the tumor cells in all organs examined. In conclusion, Fab'-SIL[DXR] formulations should receive clinical evaluation as adjuvant therapy of neuroblastoma...
  42. ncbi request reprint Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment
    Chiara Brignole
    Differentiation Therapy Unit, Laboratory of Oncology, G Gaslini Children s Hospital, Largo G Gaslini 5, 16148 Genoa, Italy
    Cancer Lett 197:231-5. 2003
    ..Future studies will be performed to evaluate the antitumour efficacy of the above formulations in animal models...
  43. ncbi request reprint Ligand-targeted liposomal therapies of neuroblastoma
    Fabio Pastorino
    Differentiation Therapy Unit, Laboratory of Oncology, G Gaslini Children s Hospital, Genoa, Italy
    Curr Med Chem 14:3070-8. 2007
    ..This review will focus on the description of the most clinically relevant animal models established to test the efficacy of targeted liposomal anti-tumour formulations for the treatment of Neuroblastoma...
  44. ncbi request reprint Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models
    Fabio Pastorino
    Differentiation Therapy Unit, Laboratory of Oncology, G Gaslini Children s Hospital, 16148 Genoa, Italy
    Clin Cancer Res 9:4595-605. 2003
    ....
  45. ncbi request reprint Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy
    Fabio Pastorino
    Differentiation Therapy Unit, Laboratory of Oncology, G Gaslini Children s Hospital, Largo G Gaslini 5, 16148 Genoa, Italy
    Cancer Res 63:7400-9. 2003
    ..This combined strategy has the potential to overcome some major limitations of conventional chemotherapy...
  46. doi request reprint Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin
    Fabio Pastorino
    Differentiation Therapy Unit, Laboratory of Oncology, G Gaslini Children s Hospital, 16148 Genoa, Italy
    J Control Release 126:85-94. 2008
    ..Our data indicate the increasing cell sensitivity to DXR by c-myc-asODNs as a promising basis for developing novel anti-tumor strategy against advanced melanoma...
  47. ncbi request reprint High efficiency entrapment of antisense oligonucleotides in liposomes
    Darrin D Stuart
    Chiron Corporation, Cancer Pharmacology, Emeryville, CA 94608, USA
    Methods Enzymol 387:171-88. 2004
  48. ncbi request reprint Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs
    Chiara Brignole
    Laboratory of Oncology, Gaslini Children s Hospital, Genoa, Italy
    J Natl Cancer Inst 96:1171-80. 2004
    ..Because antisense oligonucleotides containing CpG motifs can stimulate immune responses, we evaluated the effect of CpG-containing c-myb antisense oligonucleotides encapsulated within targeted liposomes...
  49. ncbi request reprint Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL
    Sajid Hussain
    Department of Pharmacology, University of Bern, Friedbuhlstrasse 49, CH 3010 Bern, Switzerland
    Mol Cancer Ther 5:3170-80. 2006
    ..Our data show the promise of EpCAM-specific drug delivery systems, such as antisense-loaded immunoliposomes, for targeted cancer therapy...
  50. ncbi request reprint Cytotoxic N-[4-(3-aryl-3-oxo-1-propenyl)phenylcarbonyl]-3,5-bis(phenylmethylene)-4-piperidones and related compounds
    Jonathan R Dimmock
    College of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan, Canada S7N 5C9
    Eur J Med Chem 37:961-72. 2002
    ....
  51. ncbi request reprint Cytotoxic analogues of 2,6-bis(arylidene)cyclohexanones
    Jonathan R Dimmock
    College of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Sask, Saskatoon, Canada, S7N 5C9
    Eur J Med Chem 38:169-77. 2003
    ..A number of lead molecules emerged from this investigation as well as guidelines for future expansion of these series of compounds...
  52. ncbi request reprint Cytotoxic 1,4-bis(2-oxo-1-cycloalkylmethylene)benzenes and related compounds
    Jonathan R Dimmock
    College of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan, Canada S7N 5C9
    Eur J Med Chem 37:35-44. 2002
    ....
  53. ncbi request reprint Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography
    Jonathan R Dimmock
    College of Pharmacy and Nutrition, Department of Chemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Canada
    J Med Chem 45:3103-11. 2002
    ..The compounds displayed little murine toxicity, which favors the decision to develop these molecules as cytotoxic and anticancer agents...
  54. ncbi request reprint Cytotoxic 1,3-diarylidene-2-tetralones and related compounds
    Jonathan R Dimmock
    College of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan, Canada S7N 5C9
    Eur J Med Chem 37:813-24. 2002
    ..The compounds were well tolerated when administered intraperiteonally to mice. Thus these novel enones are promising prototypic molecules due to their potent cytotoxic properties and lack of significant murine toxicity...